Helicobacter Pylori
Conditions
Keywords
Helicobacter pylori, phototherapy, peptic ulcer, gastric cancer
Brief summary
This purpose of this study is to determine whether phototherapy can be used to safely and effectively treat H pylori.
Detailed description
H pylori causes almost all peptic ulcers and many gastric cancers and is widely prevalent worldwide. Treatment by multiple antibiotics and proton pump inhibitors is effective but are compromised today by significant non compliance due to side effects and duration of required treatment. Also, the increase in antibiotic resistance coupled with the decreased availability of new antibiotics project a significant population of patients who will not be treatable with antibiotics. A special, visible-light based phototherapy system has been demonstrated to significantly decrease the viability of H pylori in vitro and in a brief clinical experiment. This study will evaluate the safety and short term efficacy in up to 60 patients of the phototherapy system to treat H pylori.
Interventions
DEVICEPhototherapy
Sponsors
LumeRx
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* Age \> 18 and \< 90 * Documented positive for H. pylori infection by urease breath test, stool antigen or histology within thirty days prior to procedure * Willing to comply with study requirements * Able to undergo endoscopic esophagogastroduodenoscopy (EGD) with biopsy
Exclusion criteria
* History of gastric or duodenal carcinoma * History of prior gastric or duodenal surgery * Oral or intravenous antibiotics use within previous one month * Use of bismuth subsalicylate (Pepto Bismol) within previous one month * Use of photosensitizing drugs or nutritional supplements within previous one month * Active peptic ulcer disease (gastric or duodenal ulcer) * Esophagitis Grade II or higher * Oral or intravenous antibiotics use within previous one month * History of a bleeding disorder or anti-coagulant use that would prevent biopsy * PPI treatment two weeks prior to the scheduled endoscopy * Positive Pregnancy Test * Known porphyria * Suffer from phenylketonuria (PKU) * Signs of jaundice * Weight \< 100 lb or \> 250 lb * Previously enrolled in this study * Participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of this study * The subject is inappropriate for study participation, as determined by the Investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Negative urease breath test at five weeks post procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| Procedural Side Effects | — |
| Negative urease breath test at 5 days post procedure | — |
| Reduction in acute post treatment bacterial population with respect to pretreatment samples | — |
Countries
United States
Outcome results
None listed